ArticleCell2025
Immunotherapy-related cognitive impairment after CAR T cell therapy in mice.
Abstract read
In one paragraph
Article in Cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- mRNA CAR T cells promote tolerable, tunable therapy in preclinical high grade glioma models.Molecular therapy. Oncology · 2026Article
- CAR-T cell therapy: potential for paediatric brain tumours-an update.Journal of neuro-oncology · 2026Review
- Juvenile influenza can impair myelin development and adult behavior through chemokine signaling in mice.bioRxiv : the preprint server for biology · 2026Article
- Anti-CD19 CAR T Cells in Autoimmune Encephalitis: Inflammation Controlled, Neurodegeneration Unchecked?Annals of clinical and translational neurology · 2026Article
- Immunotherapy for Diffuse Midline Glioma: From Preclinical Modeling to Clinical Translation.Cancers · 2026Review
- Cognitive dysfunction associated with cellular immunotherapy for cancer.Neuro-oncology advances · 2026Review
- The neurobiology of survivorship: Cognitive consequences of modern oncology.Neuro-oncology advances · 2026Review
- Long-Term Cognitive Impairment After CAR-T Therapy Versus Autologous Stem Cell Transplantation: A Propensity Score-Matched Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Metabolic Crosstalk Between Host and Tumor as a Circuit of Resilience in Cancer Therapy.Cells · 2026Review
- Intranasal Adipose-Derived MSC Extracellular Vesicles Confer Sustained Cognitive Improvement and Suppress Alzheimer's Pathology in APP/PS1 Mice.Biomolecules · 2026Article
- Ginsenoside Rg1 Ameliorates the Learning and Memory Deficits of 5xFAD Mice by Inhibiting CCR3 Activity: Insights from In Vivo and In Vitro Investigations.Pharmaceuticals (Basel, Switzerland) · 2026Article
- PLX5622 did not alter anxiety-like behaviour and showed limited microglial depletion efficacy in a spinal cord injury model in female rats.Scientific reports · 2026Article
- Intranasal Anti-CD3 Antibody Treatment Attenuates Post-COVID Neuroinflammation and Enhances Hippocampal Neurogenesis and Cognitive Function in Mice.bioRxiv : the preprint server for biology · 2026Article
- PSMC2 serves as a potential regulatory target of EZH2 in promoting glioma progression via epithelial-mesenchymal transition.Scientific reports · 2026Article
- Ginsenoside Rg2 attenuates secondary brain injury following intracerebral hemorrhage by inhibiting NLRP3-mediated pyroptosis.Journal of neuroinflammation · 2026Article
- IGSF11-VISTA is a critical and targetable immune checkpoint axis in diffuse midline glioma.Cancer cell · 2026Article
- The promise of immunotherapy for central nervous system tumours.Nature reviews. Immunology · 2026Review
- Engineering chimeric antigen receptor CD4 T cells for Alzheimer's disease.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Mechanisms, challenges and opportunities for FLASH radiotherapy in cancer.Nature reviews. Cancer · 2026Review
- Current Status and Evolution of Immunotherapy in Glioma Management.International journal of medical sciences · 2026Review
Corrections and comments
- Update of
Authors and funding
28 authors.
Anna C GeraghtyDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA 94305, USA; Howard Hughes Medical Institute, Stanford University, Stanford, CA 94305, USA.
Lehi Acosta-AlvarezDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA 94305, USA.
Maria C RotirotiDepartment of Pediatrics, Stanford School of Medicine, Stanford, CA 94305, USA.
Selena DuttonDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA 94305, USA.
Michael R O'DeaNeuroscience Institute, NYU Grossman School of Medicine, New York, NY 10016, USA.
Wonju KimDepartment of Pediatrics, Stanford School of Medicine, Stanford, CA 94305, USA.
Vrunda TrivediDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA 94305, USA.
Rebecca MancusiDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA 94305, USA.
Kiarash ShamardaniDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA 94305, USA.
Karen MalaconDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA 94305, USA.
Pamelyn J WooDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA 94305, USA.
Naiara Martinez-VelezDepartment of Pediatrics, Stanford School of Medicine, Stanford, CA 94305, USA.
Theresa PhamDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA 94305, USA.
Noemi N Reche-LeyDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA 94305, USA.
Gabriel OtubuDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA 94305, USA.
Enrique H CastenadaDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA 94305, USA.
Kamsi NwangwuDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA 94305, USA.
Haojun XuDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA 94305, USA.
Sara B MulinyaweDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA 94305, USA.
Daniel B ZamlerDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA 94305, USA.
Lijun NiDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA 94305, USA.
Kevin CrossBrain immunology and Glia (BIG) Center and Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63130, USA.
Justin RustenhovenBrain immunology and Glia (BIG) Center and Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63130, USA.
Jonathan KipnisBrain immunology and Glia (BIG) Center and Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63130, USA.
Shane A LiddelowNeuroscience Institute, NYU Grossman School of Medicine, New York, NY 10016, USA; Department of Neuroscience and Physiology, NYU Grossman School of Medicine, New York, NY 10016, USA; Department of Ophthalmology, NYU Grossman School of Medicine, New York, NY 10016, USA; Parekh Center for Interdisciplinary Neurology, NYU Grossman School of Medicine, New York, NY 10016, USA.
Crystal L MackallDepartment of Pediatrics, Stanford School of Medicine, Stanford, CA 94305, USA; Center for Cancer Cellular Therapy, Stanford School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Robbie G MajznerDepartment of Pediatrics, Stanford School of Medicine, Stanford, CA 94305, USA; Center for Cancer Cellular Therapy, Stanford School of Medicine, Stanford, CA 94305, USA.
Michelle MonjeDepartment of Neurology and Neurosciences, Stanford School of Medicine, Stanford, CA 94305, USA; Department of Pediatrics, Stanford School of Medicine, Stanford, CA 94305, USA; Center for Cancer Cellular Therapy, Stanford School of Medicine, Stanford, CA 94305, USA; Howard Hughes Medical Institute, Stanford University, Stanford, CA 94305, USA. Electronic address: mmonje@stanford.edu.
Funding
Targeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI KEITH LLOYD LIGON · 2013 to 2026
$33.5MLeveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1MTraining Program in Translational Brain Tumor ResearchT32CA151022 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2010 to 2026
$6.6MTargeting the neuronal microenvironment in glioblastomaU19CA264504 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Michelle Monje-Deisseroth · 2021 to 2026
$6.4MGlioma Circuitry: Bridging Systems Neuroscience and CancerDP1NS111132 · NINDS · STANFORD UNIVERSITY · PI MONJE-DEISSEROTH, MICHELLE · 2018 to 2022
$5.7MDeveloping Safe and Effective GD2-CAR T Cell Therapy for Diffuse Midline GliomasR01CA263500 · NCI · STANFORD UNIVERSITY · PI MACKALL, CRYSTAL, MONJE-DEISSEROTH, MICHELLE · 2021 to 2025
$3.3MNeuronal Regulation of Low-Grade GliomagenesisR01CA258384 · NCI · STANFORD UNIVERSITY · PI David H Gutmann, Michelle Monje-Deisseroth · 2022 to 2026
$3.1MNeurotoxicity of Reactive Astrocyte-secreted Lipids in Neurodegenerative DiseaseR01EY033353 · NEI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Shane Liddelow · 2022 to 2026
$2.5MFunctional interrogation of region-specific reactive astrocyte factors in neuroinflammationF31NS135948 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI O'DEA, MICHAEL RYAN · 2024 to 2025
$85kNCI NIH HHS P50 CA165962NCI NIH HHS R01 CA258384NCI NIH HHS R01 CA263500NCI NIH HHS T32 CA009302NCI NIH HHS T32 CA151022NCI NIH HHS U19 CA264504NEI NIH HHS R01 EY033353NINDS NIH HHS DP1 NS111132NINDS NIH HHS F31 NS135948
Abstract
Immunotherapies have revolutionized cancer care for many tumor types, but their potential long-term cognitive impacts are incompletely understood. Here, we demonstrated in mouse models that chimeric antigen receptor (CAR) T cell therapy for both central nervous system (CNS) and non-CNS cancers impaired cognitive function and induced a persistent CNS immune response characterized by white matter microglial reactivity, microglial chemokine expression, and elevated cerebrospinal fluid (CSF) cytokines and chemokines. Consequently, oligodendroglial homeostasis and hippocampal neurogenesis were disrupted. Single-nucleus sequencing studies of human frontal lobe from patients with or without previous CAR T cell therapy for brainstem tumors confirmed reactive states of microglia and oligodendrocytes following treatment. In mice, transient microglial depletion or CCR3 chemokine receptor blockade rescued oligodendroglial deficits and cognitive performance in a behavioral test of attention and short-term memory function following CAR T cell therapy. Taken together, these findings illustrate targetable neural-immune mechanisms underlying immunotherapy-related cognitive impairment.
Indexed as
Cognitive DysfunctionImmunotherapyImmunotherapy, AdoptiveReceptors, Chimeric AntigenAnimalsCytokinesDisease Models, AnimalFemaleHippocampusHumansMaleMiceMice, Inbred C57BLMicrogliaT-LymphocytesCytokinesReceptors, Chimeric Antigenacute lymphoblastic leukemiaALLcancer therapy-related cognitive impairmentCAR T cell therapychemokinesCRCIdiffuse midline gliomaDMGimmunotherapy-related cognitive impairmentIRCImicrogliamyelinoligodendrocytes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.